Patients receiving renal replacement therapy with hemodialysis and taking nsaids during the covid-19 pandemic


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. to study the features of the use of nonsteroidal anti-inflammatory drugs (nsaids) in patients receiving programmed hemodialysis (HD) during the covid-19 pandemic. material and methods. a survey of 196 patients hd was performed. results. more than half of the patients (iio/56%) receiving program hd took nsaids during the previous 6 months, 75.5% patients took nsaids during the last month, of which 27.7% took medications daily. the main reasons for taking nsaids are joint pain, headache. Almost half of the patients (47%) had a new coronavirus infection (NCI), of which 58.7% patients regularly took nsaids, and 28.2% patients - daily during the last month; 53.8% patients among the patients who did not undergo nici regularly took nsaids, and (27.з% - daily during the last month. Conclusion. More than half (56%) of patients receiving program hd often and for a long time take nsaids, despite the use of anticoagulants during hemodialysis. there was a slight increase in the frequency of nsaid intake in patients with covid-19 infection. considering the fact that the use of nsaids in this category of patients is associated with a high risk of complications, the urgent task remains to timely clarify the fact of the patient's use of nsaids, correction of therapy, selection of the safest drugs and their use regimens.

Full Text

Restricted Access

About the authors

Andrey P. Rebrov

Saratov State Medical University named after V.l. Razumovsky, Ministry of Health of Russian Federation

Email: andreyrebrov@yandex.ru
MD, professor, head of hospital therapy department Saratov, Russia

Elena V. Grigoryeva

Saratov State Medical University named after V.l. Razumovsky, Ministry of Health of Russian Federation

Email: lek133@yandex.ru
PhD, assistant of professor of hospital therapy department Saratov, Russia

Gennady S. Petrov

Saratov State Medical University named after V.l. Razumovsky, Ministry of Health of Russian Federation

Email: petrovgs2007@yandex.ru
assistant of hospital therapy department Saratov, Russia

Maxim A. Polidanov

Saratov State Medical University named after V.l. Razumovsky, Ministry of Health of Russian Federation

Email: maksim.polidanoff@yandex.ru
student Saratov, Russia

Ivan E. Kondrashkin

Saratov State Medical University named after V.l. Razumovsky, Ministry of Health of Russian Federation

Email: ivan.kondrashckin@yandex.ru
student Saratov, Russia

Igor S. Blokhin

Saratov State Medical University named after V.l. Razumovsky, Ministry of Health of Russian Federation

Email: ig.bloxin2010@yandex.ru
student Saratov, Russia

Darya A. Tyapkina

Saratov State Medical University named after V.l. Razumovsky, Ministry of Health of Russian Federation

Email: orchidaceae.2017@yandex.ru
student Saratov, Russia

Alexandra A. Boroday

Saratov State Medical University named after V.l. Razumovsky, Ministry of Health of Russian Federation

Email: alexandra.108@mail.ru
student Saratov, Russia

References

  1. БелоцерковскаяЮ.Г, РомановскихА.Г., СмирновИ.П., СинопальниковА.И. Долгий COVID-19. Consilium Medicum. 2021;23(3):261-68
  2. Day M. Covid-19: Ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368:m1086. Doi: https://doi.org/10.1136/
  3. Nahin R.L. Estimates of pain prevalence and severity in adults: United States, 2012. J. Pain. 2015;16:769-80. doi: 10.1016/j.jpain.2015.05.002.
  4. FitzGerald G.A. Misguided drug advice for COVID-19. Science. 2020;367(6485):1434. doi: 10.1126/science.abb8034.
  5. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020;368:m1185. Doi: https://doi.org/10.1136/bmj.m1185.
  6. Davison S.N., Koncicki H., Brennan F. Pain in chronic kidney disease: a scoping review. Semin. Dial. 2014;27:188-204. doi: 10.1111/sdi.12196.
  7. Ребров А.П., Григорьева Е.В., Петров Г.С. и др. Пациенты, получающие заместительную почечную терапию гемодиализом, и прием НПВС:реальная клиническая практика. Клин. нефрология. 2021;4:43-7. Doi: https://dx.doi.org/10.18565/nephrology.2021.4.00-00.
  8. Chih-Cheng Hsu, Yu-Kang Chang, Yueh-Han Hsu, et al. Association of Nonsteroidal Anti-inflammatory Drug Use With Stroke Among Dialysis Patients. Kidney Int. Rep. 2017;2(3):400-9. doi: 10.1016/j.ekir.2017.01.004.
  9. Samar Abd El Hafeez, Reem Hegazy, Yasmine Naga, et al. Non-steroidal antiinflammatory drugs among chronic kidney disease patients: an epidemiological study. J. Egypt. Public. Health Assoc. 2019;94(1):8. doi: 10.1186/s42506-018-0005-2.
  10. Шилов Е.М., Котенко О.Н., Шилова М.М. и др. Эпидемиология COVID-19 у больных, получающих заместительную почечную терапию в Российской Федерации: итоги 2020 г. Клин. нефрология. 2021;1:5-12. [Shilov E.M., Kotenko O.N., Shilova M.M., et al. Epidemiology of COVID-19 in patients, receiving renal replacement therapy in the Russian Federation: results of 2020. Clin. Nefrol 2021;1:5-12 (In Russ.)].
  11. Шилов Е.М., Шилова М.М., Румянцева Е.И. и др. Эпидемиология COVID-19 у больных, находящихся на заместительной почечной терапии, в Российской Федерации в 2021 г. (краткий отчет) Клин. нефрология. 2022;2:6-8.
  12. Ingrasciotta Y., Sultana J., Giorgianni F., et al. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in southern Italy. PLoS ONE. 2014;9(2):e89072. Doi: https://doi.org/10.1371/journal.pone.0089072.
  13. Kamarzarian A., Pham P.M.T., Pham P.T.T., et al. Pharmacology In: Pham P-C, Pham P-T (eds). Nephrology and Hypertension Board Review. Philadelphia, PA: Wolters Kluwer. 2016, P. 334-54.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies